STAAR Surgical Company reported a first-quarter performance that underscores the viability of its independent strategy after shareholders voted down a proposed acquisition by Alcon. The Lake Forest-based maker of implantable collamer lenses posted results that materially exceeded consensus expectations, prompting markets to reprice the company well above Alcon’s final takeover offer.
Shares reached $33 by May 18, 2026, a level comfortably above Alcon’s last sweetened bid of $30.75 per share. The result follows a bruising period that included a proxy fight, a contested acquisition attempt and a sweeping governance reset that replaced prior leadership and installed interim co-chief executives to shepherd a standalone plan.
Financial rebound and operating turnaround
STAAR reported GAAP earnings per share of $0.10 for the first quarter, double the consensus analyst estimate of $0.05. Quarterly net sales totaled $93.5 million, a 119.6% year-over-year increase that also exceeded the analyst projection of $78.74 million.
The performance represents a marked recovery from the prior-year period of acute operational stress. In Q1 2025 the company recorded net sales of $42.6 million after it cut shipments to Chinese distributors to allow channel inventories to clear. That decision followed a year in which demand softened and distributor stockpiles built up in China.
Operating income swung into positive territory at $8.0 million, compared with an operating loss of $(57.4) million in the year-ago quarter. Adjusted EBITDA also moved sharply higher, producing $24.4 million of profit versus a $26.3 million loss in Q1 2025. The company attributed the improvement to tighter cost controls, renewed demand and restored execution under the interim leadership team.
Proxy fight, governance change and leadership focus
The rebound comes several months after shareholders rejected Alcon’s takeover proposal. Alcon initially made an unsolicited $1.5 billion offer at $28.00 per share in August 2025 and later increased that to a $1.6 billion best-and-final bid valued at $30.75 per share in December 2025. Activist investor Broadwood Partners urged investors to resist the deal, and at a special shareholder meeting the majority voted against the merger. Following the vote, STAAR and Alcon terminated their agreement on January 6, 2026, and the company implemented a governance reset that included the addition of three directors as well as the appointment of Warren Foust and Deborah Andrews as interim Co-CEOs.
The interim leaders set out clear operational priorities centered on revenue growth, profit expansion and accelerating product innovation. In their initial shareholder letter they wrote, "We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion, and we expect to advance Product Innovation over the balance of the year."
Reflecting on the first 100 days of the transition, Co-CEO Warren Foust described a cultural shift and renewed alignment in comments provided to Investing.com:
"STAAR has always had a strong culture, but I believe it has become even stronger over the last several months. I’m incredibly proud of how our teams around the world came together with resilience and professionalism during a period of uncertainty. Today, there is real energy and alignment across the organization as our teams focus on the opportunities ahead and the true earning power of the business is beginning to reveal itself as many of the short-term disruptions move behind us. The key was creating clarity and reducing distractions so our teams could focus on what they do best. We have incredibly talented people around the world who are advancing refractive surgery through our Collamer lens technology, and once the organization regained alignment around priorities, the focus naturally returned to execution, innovation and supporting customers and patients."
Co-CEO Deborah Andrews emphasized the link between financial discipline and long-term independence, saying in a statement to Investing.com, "We moved forward by taking decisive cost actions, staying focused on execution, and maintaining confidence in the long-term strength of our ICL franchise. As temporary headwinds eased, demand returned and our leaner operating model drove strong profitability. This quarter reinforces that STAAR has the technology, discipline, and execution to succeed as a standalone company and create long-term shareholder value."
Regional drivers - China and the U.S.
Regional performance data show that China led the rebound. Net sales in China hit $47.4 million for the quarter, supported by the commercial introduction of the premium EVO+ implantable collamer lens. Management reports that distributor inventory levels in China have stabilized to targeted ranges, aligning current sell-in more closely with organic patient demand.
U.S. sales also advanced, with STAAR crossing a milestone of more than $6 million in quarterly net sales, an increase of 22% year-over-year. That domestic gain occurred despite broader weakness in the U.S. refractive surgery market, where laser-based procedures have continued to contract.
On the company’s earnings call, Co-CEO Warren Foust cited industry data from the Refractive Surgery Council showing that U.S. laser vision correction surgical volumes declined by about 7% in Q1 2026, extending a steeper fall of roughly 15% on a year-over-year basis. Management and clinical advocates have highlighted the shifting preference toward reversible, lens-based options such as STAAR’s EVO ICL; clinical outcomes reported by Dr. Matthew Sharpe of SharpeVision indicate a 93.3% rate of vision improvement for ICLs versus 88.3% for standard corneal laser correction.
Strategy, systems upgrades and regulatory progress
To build share in the domestic market, management is reallocating marketing spend toward surgeons who are prioritizing EVO ICL in their practices. The updated marketing approach is intended to deliver a higher impact per dollar deployed by concentrating efforts in surgeons and practices most likely to adopt lens-based procedures.
Meanwhile, the company is in the early stages of a multi-year Enterprise Resource Planning rollout intended to improve visibility into operations and facilitate scalable processes. Management reported minimal disruption so far but noted the work remains in early phases.
Regulatory progress has added to the strategic runway. The company secured an FDA label expansion covering patients ages 45-60, broadening the addressable clinical population. Management framed these operational and regulatory developments as part of a longer-term effort to position the company’s lens-based portfolio for growth against an addressable market that the company notes could be very large as myopia prevalence increases globally.
Analyst views and market reaction
Investor reaction has been largely positive following the results, but analysts remain measured about forward visibility. Wedbush analyst Michael Piccolo upgraded the stock to an Outperform with a $40.00 target, calling the quarter an "inflection point for a full China rebound" and suggesting the company could exceed Wedbush’s bull case if China continues to recover and contribute incremental progress.
Across the coverage universe the consensus rating remains a Hold, with an average target price of $29.67 based on 11 analysts compiled by Investing.com. Stifel and Piper Sandler lifted their targets to $31.00 and $33.00, respectively, but both firms maintained Neutral ratings citing limited visibility.
Piper analyst Adam Maeder commented in a post-earnings note, "We still wrestle with the underlying visibility in the business and are content remaining on the sidelines for now." Stifel’s Thomas Stephan observed that "although we await better visibility into numbers, STAA is clearly on stronger footing as the end market and inventory in China improves/normalizes." Piccolo suggested the quarter could mark the beginning of a valuation re-rating and a return to historical multiples should the China rebound gather pace.
Macroeconomic and geopolitical headwinds
Management has chosen not to provide formal full-year guidance, citing macroeconomic volatility and geopolitical uncertainty. The company reported nearly $2 million in lost first-quarter sales due to disruptions linked to the current U.S.-Iran conflict, noting that the closure of the Strait of Hormuz has contributed to an energy shock that has pushed up costs and complicated global trade.
While STAAR’s management suggested Chinese demand might ultimately prove less sensitive to global energy-driven inflation than other markets - pointing to China’s strategic oil reserves and growing domestic electric vehicle adoption - they still acknowledged mixed macro signals. The shareholder letter observed that "while macroeconomic signals remain mixed, underlying demand for refractive procedures continues to grow at a moderate pace."
A geopolitical tracking data point cited in the company’s reports referenced a short-lived 5-point week-over-week dip in Chinese consumer confidence following initial price shocks from the Middle East conflict, underscoring that Chinese consumer sentiment can be affected by global energy price volatility.
Structural initiatives and supply chain positioning
Management continues to highlight structural moves designed to protect manufacturing and distribution against shifting trade policies. The company’s Nidau, Switzerland facility ensures that all lenses shipped to China avoid standard U.S.-China tariff exposure, a step management says helped ease investor anxiety after 2025’s tariff-related volatility. That manufacturing footprint does not, however, eliminate the broader macro risks tied to global energy disruptions.
The company also emphasized that demand for refractive surgery tends to be concentrated among consumers with higher disposable income and those who prioritize clinical spending. Management suggested these demographics may offer some resilience in softer economic conditions, while noting that the value consumers place on vision can support demand even amid broader discretionary spending pressures.
Where STAAR stands now
Put together, the post-proxy governance changes, a leaner cost base, an inventory reset in China and initial signs of market share capture in both China and the U.S. have helped STAAR erect a plausible standalone path. The company has demonstrated a rapid restoration of profitability and a clear pivot toward execution, but analysts and investors remain watchful for sustained evidence that normalized channel inventories and recovering procedure volumes will continue to drive top-line expansion.
While the immediate operational evidence challenges the narrative that the company required acquisition to succeed, management and analysts alike flag continued uncertainty around macro conditions, regional demand visibility and the early-stage ERP implementation. The company’s recent results provide a positive short-term data point for the standalone thesis, but the durability of the recovery will be determined in coming quarters as China demand continues to normalize and as global geopolitical factors evolve.
Summary
STAAR Surgical’s Q1 results mark a decisive operational improvement, with outsized revenue growth and a return to profitability following a period of distribution inventory imbalances and a high-profile takeover attempt. The governance reset and interim leadership have prioritized execution, product innovation and cost discipline. China’s recovery, powered in part by the EVO+ ICL launch, and a targeted U.S. marketing push have been central to the rebound. Analysts applaud the progress but emphasize persistent visibility and macro risks that justify continued caution.